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Non-canonical NF-κB-pathway signaling is integral in immunoregulation. Heterozygous
mutations in NFKB2 have recently been established as a molecular cause of
common variable immunodeficiency (CVID) and DAVID-syndrome, a rare condition
combining deficiency of anterior pituitary hormone with CVID. Here, we investigate
15 previously unreported patients with primary immunodeficiency (PID) from eleven
unrelated families with heterozygous NFKB2-mutations including eight patients with
the common p.Arg853∗ nonsense mutation and five patients harboring unique novel
C-terminal truncating mutations. In addition, we describe the clinical phenotype of
two patients with proximal truncating mutations. Cohort analysis extended to all 35
previously published NFKB2-cases revealed occurrence of early-onset PID in 46/50
patients (mean age of onset 5.9 years, median 4.0 years). ACTH-deficiency occurred
in 44%. Three mutation carriers have deceased, four developed malignancies. Only
two mutation carriers were clinically asymptomatic. In contrast to typical CVID, most
patients suffered from early-onset and severe disease manifestations, including clinical
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signs of T cell dysfunction e.g., chronic-viral or opportunistic infections. In addition,
80% of patients suffered from (predominately T cell mediated) autoimmune (AI)
phenomena (alopecia > various lymphocytic organ-infiltration > diarrhea > arthritis
> AI-cytopenia). Unlike in other forms of CVID, auto-antibodies or lymphoproliferation
were not common hallmarks of disease. Immunophenotyping showed largely normal
or even increased quantities of naïve and memory CD4+ or CD8+ T-cells and normal
T-cell proliferation. NK-cell number and function were also normal. In contrast,
impaired B-cell differentiation and hypogammaglobinemia were consistent features of
NFKB2-associated disease. In addition, an array of lymphocyte subpopulations,
such as regulatory T cell, Th17-, cTFH-, NKT-, and MAIT-cell numbers were
decreased. We conclude that heterozygous damaging mutations in NFKB2 represent
a distinct PID entity exceeding the usual clinical spectrum of CVID. Impairment of
the non-canonical NF-κB pathways affects function and differentiation of numerous
lymphocyte-subpopulations and thus causes a heterogeneous, more severe form of PID
phenotype with early-onset. Further characteristic features are multifaceted, primarily
T cell-mediated autoimmunity, such as alopecia, lymphocytic organ infiltration, and in
addition frequently ACTH-deficiency.
Keywords: CVID, CID, NF-kappaB signaling, DAVID-syndrome, deficiency of anterior pituitary function and variable
immunodeficiency, NF-kappaB2 clinical cases, ACTH-deficiency, autoimmunity
INTRODUCTION
Common variable immunodeficiency (CVID [MIM 607594])
is a primary antibody deficiency syndrome defined by
hypogammaglobulinemia, impaired production of specific
antibodies, increased susceptibility to (primarily sinopulmonary)
infections, and exclusion of secondary causes. The phenotype is
complex, heterogeneous, and may include additional features,
such as lymphoproliferation and autoimmunity. With an
estimated prevalence of 1/10,000–50,000 CVID is the most
common symptomatic primary immunodeficiency (PID) (1, 2).
Given that certain diagnostic criteria define CVID, it has
been termed an “umbrella diagnosis” (3). The genetic basis
of CVID is gradually being unraveled. Polygenetic inheritance
is likely in most cases, but monogenic causes have been
identified in 10–20% of affected individuals (3, 4). Importantly,
monogenetic defects may represent distinct disease entities
with particular phenotypes. Following identification in 2013
and 2015, heterozygous mutations in NFKB1 and NFKB2 now
represent the largest CVID subgroups with known monogenetic
mutations (5, 6).
NF-κB (nuclear factor kappa B) is key protein complexes
regulating the immune response to infections. Their activation
is mediated by two major pathways, the canonical NF-κB1
and non-canonical NF-κB2 pathway. The canonical pathway is
stimulated by various immune receptors and primarily mediates
rapid and broad inflammatory responses. In contrast, the
non-canonical pathway is specifically stimulated and regulates
lymphoid organ development, B cell maturation including
germinal center reactions, T cell differentiation, thymic selection,
and innate antiviral immunity (7–10). NFKB2 encodes the
cytoplasmic precursor p100, which preferentially dimerizes
with RelB. Upon pathway stimulation p100 is phosphorylated
and ubiquitinated at the C-terminal domain. Subsequently it is
converted by proteasomal processing of its C-terminal half into
the mature transcription factor subunit p52. Activated NF-κB
dimers enter the nucleus and regulate target gene expression.
Whereas transcriptional activation requires dimerization
with one Rel subunit (which provides the transactivation
domain), p52/p52 homodimers are transcriptional repressors.
The hitherto reported C-terminal heterozygous mutations
in humans disrupt the NF-κB-inducing kinase (NIK)
mediated p100 phosphorylation (7–10). Subsequently, p100
processing to p52 is abolished. Thus, despite heterogeneity of
the underlying mutation, those NFKB2 mutations result in
(functional) p52-haploinsufficiency.
Clinically, the first descriptions of patients affected by NFKB2
mutations were characterized by a combination of CVID and
ACTH insufficiency, a condition termed DAVID-syndrome
(deficit in anterior pituitary function and variable immune
deficiency) (11, 12). In addition, some patients have been
described to suffer from various degrees of autoimmunity and
trachyonychia (12–14). Since NF-κB signaling has a multitude
of diverse functions within the immune system, the hitherto
published phenotypic observations were highly heterogenic
among the affected patients. Given the pivotal role of NF-κB
in the immune system, it is conceivable that its dysregulation
may cause a more severe type of early-onset PID, inflammatory-,
autoimmune-, and malignant diseases exceeding the usual
spectrum of CVID.
To elucidate this issue, we characterized a cohort of 15 novel
patients and compared the phenotype with all 35 previously
described patients with mutations in NFKB2 (11–25). Our
aim was the identification of putative genotype-phenotype
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correlations and common disease features, thus composing the
current knowledge of the clinical and immunological phenotype
in PID due to NFKB2mutations.
METHODS
Patients
The study was reviewed and approved by the ethic commission of
the Albert-Ludwigs Universität Freiburg, University of Freiburg,
Germany, and informed and written consent for collection of
patient history, clinical data, immunological studies, as well as
for genetic analyses were obtained from the patients and their
family members.
Mutational Analysis in a CVID Patient
Cohort by Targeted Next
Generation Sequencing
Genetic analysis was performed in a large cohort of CVID
patients as previously described (5). Briefly, genomic DNA
was purified from PBMCs followed by Halo-Plex target
enrichment according to the manufacturer’s instructions
(Agilent, Waldbronn, Germany). DNA samples were treated
with a restriction-enzyme master mix and the products were
hybridized to the HaloPlex probe capture library including
the indexing primer cassettes. The target DNA was captured
by a biotin-streptavidin system with HaloPlex magnetic beads,
and the circular fragments were closed in a ligation reaction.
The captured target libraries were amplified by PCR, and
the amplified target libraries were purified with AMPure XP
beads (Beckman Coulter) and washed in ethanol. Enrichment
was validated on a BioAnalyzer or TapeStation (Agilent).
Subsequently, samples were pooled in equimolar amounts for
multiplexed sequencing on an Illumina MiSeq system. Libraries
were denatured and diluted to a final concentration of 8–12
pM. For sequencing, an Illumina Reagent Kit v.2 was used
and the following genes analyzed: AKT1, APCS, BCL6, BLNK,
BTK, CD19, CD27, CD274, CD28, CD40, CD40LG, CD79A,
CD79B, CD80, CD81, CD86, CLEC16A, CR2, CTLA4, CXCL12,
CXCR4, DCLRE1C, GATA2, ICOS, ICOSLG, IGHM, IGLL1,
IKBKB, IKBKG, IL21, IL21R, IRF4, LRBA, MLH1, MS4A1,
NFKB1, NFKB2, NFKBIA, PDCD1, PDCD1LG2, PIK3AP1,
PIK3CD, PIK3R1, PRDM1, PRKCD, PRKD1, RAG1, RAG2,
RELA, SH2D1A, STAT1, TCF3, TFRC, TGFB1, TGFB2, TGFB3,
TNFRSF13B, TNFRSF13C, TNFRSF17, TNFRSF18, TNFRSF4,
TNFSF10, TNFSF13, TNFSF13B, VAV1, VAV2.
Confirmation of Identified Sequence
Variants by Sanger-Sequencing
Genomic DNA was isolated from blood samples using QIAamp
kits (Qiagen, Hilden, Germany). Genomic fragments spanning
exons 22 and 23 of NFKB2 were amplified by PCR. PCR
primers were used for Sanger sequencing according to standard
techniques (sequences available on request). The frequency of the
identified variations was analyzed with the databases SNPbase
(http://www.ncbi.nlm.nih.gov/snp), 1,000 Genomes (http://
browser.1000genomes.org/Homo_sapiens/Info/Index), EVS
(http://evs.gs.washington.edu), Kaviar (http://db.systemsbiology.
net/kaviar/), and ExAC (http://exac.broadinstitute.org/).
NK and T Cell Assays
NK cell degranulation was performed as described (26). Briefly:
Freshly isolated PBMCs were stimulated with either with
medium alone or K562 cells (lackingMHC 1 expression) for 2.5 h
in presence of anti-CD107a-PE (BD Biosciences, Heidelberg,
Germany). Lytic exocytosis of NK cells (CD3- CD56+) are
measured by CD107a (CD107a–PE (H4A3, IgG1) degranulation.
Cytotoxicity was measured by stimulating freshly isolated
PBMCs by standard Chromium-51 release assay. K562 target
cells were labeled with 51Cr and incubated with PBMCs.
Supernatant was harvested after 4 h, transferred to lumaplates
and dried overnight. Radioactivity was determined with
TopCount NXT. NK cell percentage was measured by FACS
staining and NK to target ratio was calculated. T cell proliferation
was measured by CFSE dilution after 5–7 days of stimulation
with medium alone or PHA (1.25µg/ml) or CD3 (300 ng/ml)
with CD28 (1,000 ng/ml) or CD3/CD28 Beads (BD Biosciences)
as previously described (27).
Circulating T Follicular Helper Cell Staining
Whole blood was stained with antibodies and fixed with Optilyse
C (Beckman Coulter, Krefeld, Germany) according to the
manufacturer’s instructions. Data were acquired on a Gallios
flow cytometer (Beckman Coulter) and analyzed using FlowJo
software (version 10; Treestar, Ashland, OR, USA). Antibodies
were: CD4 PerCP (clone SK3), CXCR5 FITC (clone RF8B2) (all
from BDBiosciences, Heidelberg, Germany), CD3 PE-Cy7 (clone
UCHT1, Beckman Coulter), CD45 Pacific Blue (clone HI30),
CD45RA APC-Cy7 (clone HI100), CCR6 BV605 (clone G034E3)
(all from BioLegend, San Diego, CA, USA), CXCR3 PE (clone
WM59, R&D Systems, Minneapolis, MN, USA).
RESULTS
Molecular Details of 15 PID Patients Due to
Mutations in NFKB2
To identify the genetic origin of the disease phenotype in our
CVID cohort we employed targeted Next Generation Sequencing
(NGS). We identified 13 patients with NFKB2 mutations
affecting the C-terminal phosphorylation/ubiquitination
domain (Figure 1).
Among these, eight patients from four different families
carry the most common non-sense mutation in exon 22
(c.2557C>T; p.Arg853∗), whereas further five patients harbor
unique, previously unreported C-terminal mutations. All these
mutations were confirmed by Sanger sequencing (Figure 1B).
Despite the heterogeneity of the differentmutations all previously
described C-terminal mutations have universally been reported
to result in normal expression and cytoplasmic localization
of mutant, non-processable p100 precursors and thus in p52
haploinsufficiency (11–25) (Table 1).
In addition to these C-terminal mutations, we identified
two patients with proximal truncating mutations predicting the
expression of severely shortened p52-like proteins, instead of
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FIGURE 1 | PID-associated C-terminal NFKB2 mutations. (A) Pedigrees of the family members who participated in this study. Circles, female; squares, male; filled
symbols, affected individual with PID; open symbol, healthy family member; slash, deceased individual. Family members who underwent genetic testing are indicated
by IDs and sequence variants. (B) Sanger sequencing confirms that all NFKB2 mutations cluster within exons 22–23 and affect the C-terminus of the 900 amino acids
precursor protein p100. The mutation in Fam689 is shown as a representative for all families harboring the p.Arg853* hot-spot mutation.
the full-length p100, thereby skipping the precursor stage. The
splice donor site mutation of intron 14 in patient P3 predicts
splicing errors, such as skipping of exon 14 (resulting in a
frame-shifted variant; p.Ala443Aspfs∗5) or retention of intron
14 (resulting in a nonsense variant; p.Pro491∗). However, we
cannot exclude that other splicing errors occur. Likewise, the
2bp deletion in exon 14 (c.1416_1417delGC) in patient P4
predicts the premature termination of translation due to a shift
of the reading frame (p.Leu473Alafs∗32). Similar mutations have
previously been described in five individuals (Table 1) (28). The
novel mutations reported in the manuscript at hand have been
functionally validated and will be published separately as the
description of the molecular effects of these mutations is beyond
the clinical and phenotypic scope of this manuscript.
Case Descriptions of the Current Cohort
Previous studies indicated that the disease manifestations in
NF-κB related diseases, even among mutations carriers within
a single family, can be highly heterogeneous, ranging from
asymptomatic status to severe PID phenotypes with recurrent,
life-threatening infections. To identify common disease entities,
and to enable comparative analyses with previously published
cases, we reviewed patient records and describe the 15 PID
patients with mutations in NFKB2 from eleven different families
participating in this study in detail. Patient aliases P1-P50
in the current study were assigned according to the position
of the genetic variant within the NFKB2 locus. The original
patient identifiers as well as a chronological numbering of the
published cases is also indicated (Table 1). The clinical phenotype
is provided in Tables 2, 3, and summarized in Table 4. The
immunological phenotype is summarized inTable 5, and detailed
values of the immunological measurements are provided in
Supplemental Table S1.
Patients With C-Terminal Truncating
Mutations Causing p52 Haploinsufficiency
P19 (Fam689_02; father) suffered from recurrent respiratory
tract infections starting at the age of 5 years. He was diagnosed
with CVID at the age of 14 years when an autoimmune
thrombocytopenia (ITP) occurred. Treatment was initiated with
intravenous immunoglobulin replacement. The ITP which was
chronic recurrent over a time period of 2 years was treated with
oral steroid and pulses of intravenous immunoglobulins. At age
of 37 years an urothelial carcinomawas diagnosed and cured. The
patient is now 58 years old and besides suffering of mild arthritis
alive and well.
P20 (Fam689_03; daughter) suffered from infectious
symptoms included recurrent respiratory tract infection,
pneumonia, chronic purulent otitis media starting in her
second year of life. In addition, allergic rhinitis and atopic
dermatitis occurred. In line with this peripheral eosinophilia
with values of 700–1,000 eosinophils/µl was observed. At the
age of 2 years CVID was diagnosed. Treatment was limited to
intravenous immunoglobulin replacement. Besides mild arthritis
and recurrent folliculitis the patient is alive and well.
P21 (Fam689_01; son) suffered from pneumonia at the age
of 15 months and was subsequently diagnosed with PID due
to family history. He developed rheumatoid factor-negative
arthritis and diarrhea of unknown etiology recognized as
immunological complication. Endocrinology revealed growth
hormone deficiency and growth retardation. In addition, the
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1 21 Kuehn A1 28 2017 m son Caucasian alive c.1252G>T 13 nonsense precursor skipping p.Glu418*
2 22 Kuehn A2 63 2017 m father Caucasian alive c.1252G>T 13 nonsense precursor skipping p.Glu418*
3 48 current Fam1506_01 2018 m Caucasian alive c.1469+1 G>A 14 frameshift ex. 14 del/in.14 retained p.Pro491* p.Ala443Aspfs*5
4 47 current 6 2018 m Indian alive c.1416_1417del GC 14 frameshift precursor skipping p.Leu473Alafs*32
5 23 Kuehn B1 33 2017 f sibling Caucasian alive c.1903C>T 17 nonsense precursor skipping p.Arg635*
6 24 Kuehn B2 28 2017 m sibling Caucasian alive c.1903C>T 17 nonsense precursor skipping p.Arg635*
7 25 Kuehn B3 20 2017 m sibling Caucasian alive c.1903C>T 17 nonsense precursor skipping p.Arg635*
8 4 Chen B.II 24 2013 m European alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
9 17 Brue D1 >15 2014 m alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
10 18 Lougaris 2017 m Italian alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
11 27 Ramakrishnan I.1 41 2018 m father alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
12 28 Rae/Ramakrishnan P10/II.2 18 2018 f daughter alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
13 29 Maccari II.2 36 2017 f mother alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
14 30 Maccari III.1 9 2017 f daughter alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
15 31 Montin II-1f1 >25 2018 f mother Italian alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
16 32 Montin III-1f1 8 2018 m son Italian alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
17 33 Montin II-1f2 2018 m Italian alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
18 Nagai 29 2018 f Asian alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
19 38 current Fam689_02 58 2018 m father Caucasian alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
20 39 current Fam689_03 20 2018 f daughter Caucasian alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
21 40 current Fam689_01 15 2018 m son Caucasian alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
22 41 current Fam1404_1 53 2018 f mother Caucasian alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
23 42 current Fam1404_2 25 2018 f daughter Caucasian alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
24 43 current Fam1404_3 23 2018 f daughter Caucasian alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
25 46 current Fam1209_01 27 2018 f Caucasian alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
26 45 current Fam1485 3 2018 f Caucasian alive c.2557C>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Arg853*
27 19 Shi 18 2016 f Chinese alive c.2563A>T 22 nonsense n.-p. p100, f.p52-h.insuff p.Lys855*
28 34 current Fam981_01 18 2018 m Hispanic alive c.2611C>T 23 nonsense n.-p. p100, f.p52-h.insuff p.Gln871*
29 8 Lee I.1 >55 2014 f mother alive c.2594A>G 23 missense n.-p. p100, f.p52-h.insuff p.Asp865Gly
30 9 Lee II.2 >30 2014 m son alive c.2594A>G 23 missense n.-p. p100, f.p52-h.insuff p.Asp865Gly
31 10 Lee II.3 >25 2014 m son alive c.2594A>G 23 missense n.-p. p100, f.p52-h.insuff p.Asp865Gly
32 14 Brue B1 2014 f alive c.2594A>G 23 missense n.-p. p100, f.p52-h.insuff p.Asp865Gly
33 20 Lal >15 2017 m N. european alive c.2596A>C 23 missense n.-p. p100, f.p52-h.insuff p.Ser866Arg
34 26 Kuehn C1 14 2017 m Caucasian alive c.2596A>C 23 missense n.-p. p100, f.p52-h.insuff p.Ser866Arg
35 11 Brue A1 2014 f mother alive c.2600C>T 23 missense n.-p. p100, f.p52-h.insuff p.Ala867Val
36 12 Brue A5 12 2014 m son alive c.2600C>T 23 missense n.-p. p100, f.p52-h.insuff p.Ala867Val
37 13 Brue A6 9 2014 m son alive c.2600C>T 23 missense n.-p. p100, f.p52-h.insuff p.Ala867Val
38 44 current Fam220 56 2018 f Caucasian alive c.2603A>G 23 missense n.-p. p100, f.p52-h.insuff p.Tyr868Cys
39 15 Brue C1 15 2014 m sibling alive c.2556_2563delCCGAGACA 22 frameshift n.-p. p100, f.p52-h.insuff p.Arg853Alafs*30
40 16 Brue C3 2014 f sibling alive c.2556_2563delCCGAGACA 22 frameshift n.-p. p100, f.p52-h.insuff p.Arg853Alafs*30
41 36 current Fam246_01 32 2018 f Caucasian alive c.2557_2566delCGAGACAAGC 22 frameshift n.-p. p100, f.p52-h.insuff p.Arg853Cysfs*7
42 37 current Fam610_01 31 2018 f Iranian †  29y AML c.2561_2562delAC 22 frameshift n.-p. p100, f.p52-h.insuff p.Asp854Glufs*31
43 1 Chen A.II.2 36 2013 f mother European alive c.2564delA 22 frameshift n.-p. p100, f.p52-h.insuff p.Lys855Serfs*7
44 2 Chen A.III.1 13 2013 f daugher European alive c.2564delA 22 frameshift n.-p. p100, f.p52-h.insuff p.Lys855Serfs*7
45 3 Chen A.III.2 11 2013 m son European alive c.2564delA 22 frameshift n.-p. p100, f.p52-h.insuff p.Lys855Serfs*7
46 5 Liu II.2 26 2013 f sister Greek Cypriot alive c.2593_2600delGACAGTGC 23 frameshift n.-p. p100, f.p52-h.insuff p.Asp865Valfs*18
47 6 Liu II.3 22 2013 m brother Greek Cypriot †  22y Sur c.2593_2600delGACAGTGC 23 frameshift n.-p. p100, f.p52-h.insuff p.Asp865Valfs*18
48 Bader-Meunier patient 2 2 2018 m Caucasian †  8y HSCT c.2596_2597delAG* 23 frameshift n.-p. p100, f.p52-h.insuff p.Ser866Cysfs*19
49 35 current Fam846 12 2018 m Kosovarian alive c.2596_2597delAG 23 frameshift n.-p. p100, f.p52-h.insuff p.Ser866Cysfs*19
50 7 Lindsley 2.5 2014 m alive c.2598dupT 23 frameshift n.-p. p100, f.p52-h.insuff p.Ala867Cysfs*19
Patient details NFKB2  Mutation
n.-p. p100, f.p52-h.insuff, non-processable p100 precursor functional p52 haploinsufficiency; AML, acute myeloid leukemia; Sur, surgery; HSCT, haemopoietic stem cell transplantation;
ex, exon; in, intron; yrs, years. †Deceased. Previously unpublished patient are indicated by bold writing.
patient suffered from vitiligo (Supplemental Figure S1) and
recurrent conjunctivitis. Upon occurrence of epilepsy with an
anxiety aura a cranial MRI was performed and showed no
neuroanatomical pathology of the pituitary gland, brain stem, or
hypothalamic region. Treatment was initiated with intravenous
immunoglobulin replacement in early childhood, which was later
switched to subcutaneous immunoglobulins. The arthritis was
treated with NSAR and intra-articular steroid injections. The
endocrinological treatment was commenced with GH-injections,
and antiepileptic therapy with oxcarbazepine. Up to now, there
are no signs of ACTH deficiency and the patient is alive and well.
P22 (Fam1404_01, mother) is a female patient suffering from
early childhood on from recurrent respiratory infections. Hair
loss started at the age of 18. She had alopecia totalis at 19
years. Dermatologic findings were recurrent Herpes zoster and
rosacea. Immunological work-up revealed CVID at age 25 and
immunoglobulin substitution was initiated. Following 3 events
of pneumonia during 1 year at 50, pulmonary work-up showed
arterial hypertonia and small airways disease, but no signs of
bronchiectasis. The patient is now 52 years old, alive and well
under continuous immunoglobulin substitution.
P23 (Fam1404_02, daughter) suffered from recurrent upper-
and lower respiratory infections since early childhood on. Aged
4 years, she was diagnosed with CVID and immunoglobulin
replacement was initiated. At 11 years she presented autoimmune
thrombocytopenia treated with steroids and Rituximab. Chest-
CT showed bilateral lower andmiddle lobes bronchiectasis. She is
now 24 years-old with recurrent herpes labialis, cutaneous herpes
infections, herpes zoster and rosacea. In addition, she suffers
from episodes of diarrhea of unknown etiology.
P24 (Fam1404_03, daughter) presented with neonatal
pneumonia with full recovery. At the age of 1 year,
hypogammaglobinemia was detected and IgG replacement
therapy was initiated. Aged 13 years, she suffered from
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1 p.Glu418* Y RI inf 5 Y Y Y n n Y
2 p.Glu418* n RA 48 n n n n n Y Y (MTX,Adal)
3 p.Ala443Aspfs*5 Y 7 Y Y Y n n Y n n
4 p.Leu473Alafs*32 Y HLH 2 4 n n n n HLH, EBV triggered n n Y (GC, Eto, CsA)
5 p.Arg635* Y sev EBV 14 14 Y Y Y rec HSV-l, HPV, OMyc soor-eso, EBV, CMV Y
6 p.Arg635* Y 12 Y Y Y rec thrush, warts PcJ-Pneumonia n
7 p.Arg635* n asymptomatic n Y n n n n
8 p.Arg853* Y RI <2 10 Y Y Y
9 p.Arg853* Y Alopecia 4 HGG (1,5) Y
10 p.Arg853* Y growth delay 1 sev HGG (1,3) Y n n Y
11 p.Arg853* Y RI ch 23 Y n n Y (Ritux)
12 p.Arg853* Y RI, RTA 2 6 Y Y Y sev molluscum absces, septic arthritis Y Y (GC)
13 p.Arg853* Y Alopecia ch 16 Y Y Y Pericarditis
14 p.Arg853* Y Alopecia, RI 2 2 Y Y Y CMV, EBV, Toxop 
15 p.Arg853* Y RI 6 6 Y
16 p.Arg853* Y FH 1 sev. HGG (1)
17 p.Arg853* Y RI 6 6 Y
18 p.Arg853* Y Alopecia ch HGG (ch) Y (GC)
19 p.Arg853* Y RI 5 5 Y Y n n n Y n n
20 p.Arg853* Y RI 2 2 Y Y n folliculitis n Y n n
21 p.Arg853* Y RI 1 1 Y Y n n rec. Conjunctivitis Y n Y (GC)
22 p.Arg853* Y RI <5 25 Y Y n HZ n Y n Y (ti GC)
23 p.Arg853* Y RI 4 4 Y Y Y rec HSV-l, cut. HSV, HZ n Y n Y (Ritux)
24 p.Arg853* Y RI 0 panHGG(1) Y Y n rec HSV-l, abscess episcleritis Y n n
25 p.Arg853* Y RI 6 9 Y Y n HZ, rec HSV-l, cut HSV mild hepatopathy Y n n
26 p.Arg853* Y RI 1 1 Y n n n n Y Y n
27 p.Lys855* Y Alopecia, RI 4 18 Y Y oral candidiasis
28 p.Gln871* Y RI 2 6 Y Y Y rec HSV-l Men Y Y n
29 p.Asp865Gly Y Alopecia, RI 11 35 Y Y peridontitis, abscess giardiasis Y n n
30 p.Asp865Gly Y Alopecia <14 panHGG (20) n n n n n
31 p.Asp865Gly Y RI ch panHGG (inf) Y Y furunculosis Y
32 p.Asp865Gly Y RI 2 3 Y Y sev VZV pneu. bacteremia Y
33 p.Ser866Arg Y ACTHdef 7 11 Y n n n n
34 p.Ser866Arg n ACTHdef 8 HGG (10) n n molluscum
35 p.Ala867Val Y RI <8 8 Y Y septicemia, sep shock
36 p.Ala867Val n asymptomatic n n n n n
37 p.Ala867Val Y RI <9 mod HGG Y Y Y
38 p.Tyr868Cys Y RI 31 31 Y Y n n chronic hepatitis B Y n Y (ti GC)
39 p.Arg853Alafs*30 Y <4 4 Y sev influenza, Men Y
40 p.Arg853Alafs*30 Y mild HGG n n
41 p.Arg853Cysfs*7 Y RI <5 6 Y Y Y n n Y n Y (Ritux)
42 p.Asp854Glufs*31 Y AI-hepatitis 5 23 Y Y n n PcJ-Pneumonia Y n Y
43 p.Lys855Serfs*7 Y RI ch 30 Y Y rec HSV-l giardia Y
44 p.Lys855Serfs*7 Y RI 2 6 Y n rec HSV-l giardia, candida Omyc Y
45 p.Lys855Serfs*7 Y RI 2 panHGG (3,5) Y Y rec HSV-l Y
46 p.Asp865Valfs*18 Y sev VZV / RI 1,1 //3 9 Y Y Y sev VZV Mb. Kansasii infection Y Y (GC, Ritux)
47 p.Asp865Valfs*18 Y Men 1 7 Y Y Y VZV Nm Men Y Y (GC, CP)
48 p.Ser866Cysfs*19 Y panniculitis 1 panHGG (1,8) Y Y samonella Y Y (GC, aIL1, aTNF)
49 p.Ser866Cysfs*19 Y RI 0.8 7 Y Y Y rec HSV-l, cut HSV, HZ chron. CMV, soor-eso Y n n
50 p.Ala867Cysfs*19 Y Alopecia, RI 2 panHGG (1,5) Y n n n Y n
TreatmentClinic Infection profile
Adal, Adalimumab; absc, abscess; ACTHdef, ACTH-deficiency; AI, autoimmune; aIL1, anti-IL-1-therapy; ch, childhood; CP, cyclophosphamide; CMV, Cytomegaly Virus; cut, cutaneous;
EBV, Epstein Barr virus; GC, glucocorticoids; HGG, hypogammaglobulinemia; HLH, hemophagocytic lymphohistiocytosis; HSV, herpes simplex virus; HSV-l, herpes labialis; HPV, human
papilloma virus; HZ, herpes zoster; inf, infancy; Men, meningitis; mod, moderate; n, normal/negative (white); Nm, Neisseria meningitides; OMyc, onychomycosis; PcJ, Pneumocystis
jirovecii; pneu, pneumococcal; rec, recurrent; RTA, renal tubular acidosis; RI, respiratory infections; Ritux, Rituximab; sev, severe; soor-eso, soor-esophagitis; SP, Streptococcus
pneumonia; ti, topical/inhaled; Toxop, Toxoplasma gondii; trans, transitory; VZV, varicella zoster virus; Y, yes/present (black). No/insufficient information is indicated in dark gray.
aseptic meningitis. At 16 years she had nephrotic syndrome,
confirmed by renal biopsy (cause unknown). She had suffered
from episcleritis, with two relapses; since last one no further
complaints. She reported a soft tissue infection on the thumb,
staphylococcus aureus was isolated. Influenza A virus infection
was reported last year. In addition, she has recurrent labial
herpes infections, upper respiratory infections around six times
per year (which require antibiotic therapy) and chronic diarrhea
of unknown etiology. Currently, she is alive and stable under
immunoglobulin replacement therapy.
P25 (Fam1209_01) is a female patient of 27 years presenting
from childhood on with recurrent bronchitis and pneumonias.
At the age of 6 years, she suffered from pneumonia and aseptic
meningitis. During laboratory work-up hypogammaglobinemia
was detected and immunoglobulin replacement started.
She shows an elevation of liver enzymes from the age of
17 years until today with negative virology work-up. She
suffers from recurrent HSV-1 outbreaks since childhood.
Upon occurrence of genital herpes systemic therapy with
acyclovir became necessary. She is alive, under immunoglobulin
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TABLE 3 | Clinical features, neurology, endocrinology, and autoimmunity in patients with NFKB2 mutations.





























1 p.Glu418* n n liver PSC SM/atypLL n
2 p.Glu418* n n Y n
3 p.Ala443Aspfs*5 n n n n n n DUE n n GI eczema, vitiligo n n n
4 p.Leu473Alafs*32 n n n n n n n n n n n SM/HLH n n
5 p.Arg635* n n DUE ILD, BO SM T-LGL/BCC (22)
6 p.Arg635* n n DUE SM n
7 p.Arg635* n n n n n n n n n n n
8 p.Arg853* DevD, asep Men Y T1CM Y totalis (10) n Tg, TPO skin, ILD, CNS pso derm Y n
9 p.Arg853* Y (7) n hypoplasia Y totalis (4) n
10 p.Arg853* Y (4) HT-H Y totalis (4) n
11 p.Arg853* n negACAA nHL (23)
12 p.Arg853* n Y totalis (5) ACAA kidney, lung RTA n
13 p.Arg853* Y areata (ch) TPO (ACAAneg) ON Y n
14 p.Arg853* Y Y totalis (2) TPO, ACAA Y n
15 p.Arg853* Y (12) LPP n
16 p.Arg853* Y (6) n n n n n n n
17 p.Arg853* Y (10) GH def, HT-H n
18 p.Arg853* Y (ch) Y totalis (ch) skin pso derm Y
19 p.Arg853* n n n n n ITP n Y TPO n n n n UroCa (37)
20 p.Arg853* n n n n n n n Y n n AE, AR, Eos n n n
21 p.Arg853* epilepsy n GH def n n n n DUE Y TPO n Vitiligo n n n
22 p.Arg853* n n n n Y (19) n n n n n rosacea, AT n n n
23 p.Arg853* n n n n n ITP DUE n n n rosacea n n n
24 p.Arg853* asep Men n n n n n n IBD n n CNS? nephrotic syn n n n
25 p.Arg853* asep Men n n n n n n n n CNS? n n n n
26 p.Arg853* n n n n n n n n n n n n n n
27 p.Lys855* n Y (16) Y totalis (4) IA2 (negANA/ANCA) MC-neph n
28 p.Gln871* n Y n n n n DUE n ANA n n n Y n
29 p.Asp865Gly asep Men n n areata (11) n DUE Y n aqua Urti n
30 p.Asp865Gly n n totalis (14) n n n n n n
31 p.Asp865Gly n n totalis (8) n n n n n n
32 p.Asp865Gly absence seiz Y (5) hypoplasia n n neg pitAA n
33 p.Ser866Arg Y (7) GH def n neg pitAA n
34 p.Ser866Arg Y (7) GH def n n trans synovitis n n
35 p.Ala867Val Y (15) n n red bodyhair neg pitAA n
36 p.Ala867Val n n n n
37 p.Ala867Val n n n n
38 p.Tyr868Cys depression n n n n n n Y n n pso derm, RPC n Y n
39 p.Arg853Alafs*30 Y (9) GH def, HT-H hypoplasia n n neg pitAA n
40 p.Arg853Alafs*30 n n n n
41 p.Arg853Cysfs*7 asep Men n n n n ITP DUE n n CNS?, lung abd hypig SM, LAP n n
42 p.Asp854Glufs*31 rec. Headaches n HT-H n n AIHA AI-E n ANA 1:320 GI, liver AE, Urticaria n Y AML (29)
43 p.Lys855Serfs*7 Bell palsy Y n n n Y n
44 p.Lys855Serfs*7 Y Y totalis (<6) n TPO Vitiligo Y n
45 p.Lys855Serfs*7 Y T1CM n n n GAD Y n
46 p.Asp865Valfs*18 Y n totalis (4) ITP (4x) DUE n ILD n
47 p.Asp865Valfs*18 ON, ence n n n n n CNS, ON, ence granu BM n
48 p.Ser866Cysfs*19 n n DUE Y n skin FTT, panniculitis n
49 p.Ser866Cysfs*19 n Y (8) Prolactemia n n n n DUE n TPO (neg pituary) GI n SM n n
50 p.Ala867Cysfs*19 n n Y totalis (1,5) n n n nepTPO, ANAneg n
Neurological & Endocrinological involvement Autoimmunity
abd hypig, abdominal hyperpigmentation; ACAA, anti-cytokine autoantibodies; ACTHdef, ACTH-deficiency; AE, atopic eczema; AI-E-AI, enteropathy; AIHA, autoimmune hemolytic
anemia; ANA, anti-nuclear antibodies; aqua Urti, aquagenic urticarial; AT, arterial hypertension; atypLL, atypical lymphoid hyperplasia; AI, autoimmune; BCC, basal cell carcinoma;
BM, bone marrow; ch, childhood; CNS, central nervous system; DevD, developmental delay; DUE, diarrhea of unknown etiology; nHL-EBVneg, non-Hodgkin lymphoma (EBV neg);
ence, encephalitis; Eos, eosinophilia; epid, epidermis; GAD, anti-Glutamat-Decarboxylase-antibodies; GI, gastrointestinal; gran BM, granulomatous disease of the bone marrow; GH,
growth hormone; HT-H, Hypothyroidism; IA2, anti-Tyrosin-Phosphatase-autoantibody; ILD, interstitial lung disease; ITP, immune thrombocytopenia; inf, infancy; LAP, lymphadenopathy;
LPP, lichen planus pigmentosus; MC-neph, minimal change nephropathy; mod, moderate; n, normal/negative (white); Nm, Neisseria meningitides; ON, optic neuritis; pita, pituitary
autoantibodies; pneu, pneumococcal; OP, post-OP gastrointestinal bleeding; PSC, primary sclerosing cholangitis; pso derm, psoriasifrom dermatitis; rec, recurrent; RTA, renal tubular
acidosis; seiz, seizures; sev, severe; SM, splenomegaly; T-LGLL, T-LGL leukemia; T1CM, type 1 chiari malformation; Tg, thyroglobulin; TPO, thyroperoxidase; UroCa, urothelial carcinoma;
AR, allergic rhinitis; Y, yes/present (black). No/insufficient information is indicated in dark gray.
replacement therapy and acyclovir prophylaxis for recurrent
herpes infections.
Female P26 (Fam1485; daughter) was referred to immunology
service at the age of 1 year after identification of low
immunoglobulin levels following admission to high dependency
unit for H1N1 infection, and family history of CVID in the
mother (Pt. could not be included in this study). She had normal
antenatal and neonatal period and first became unwell at 5.5
months of age when she was admitted for H1N1 infection
requiring CPAP respiratory support. She was found to have
low immunoglobulin levels and absent responses to tetanus and
pneumococcal conjugate vaccines. The history of infections was
otherwise unremarkable apart from one episode of otitis media
that resolved with a course of oral antibiotics. Her mother was
found to have hypogammaglobinemia at 18 months of age and
had been on immunoglobulin replacement since. P26was started
on immunoglobulin replacement and antibiotic prophylaxis with
good effects. She has not experienced any other major infection
since. She has mild eczema but nil else and is growing and
developing well.
The male P28 (Fam981_01) was conceived by in vitro
fertilization and presented in early childhood with recurrent
respiratory tract infections, pneumonia, otitis media, bronchitis,
chronic sinusitis and diarrhea. CVID was diagnosed at the age
of 6 years and immunoglobulin substitution initiated. Chest-CT
showed bilateral lower lobe bronchiectasis. At the age of 11 years,
he suffered of an episode of bacterial meningoencephalitis with
full neurological recovery. Except for recurrent herpes labialis
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TABLE 4 | Summary of the major clinical manifestations of NF-κB2
haploinsufficiency.
Patient characteristics Total Percentage
n = 50














Herpes disease 13 38
Candida disease 6 20




Bac. Meningoencephalitis 3 6
Other severe bac. Infections 3 6
Giardiasis 3 6
NEUROLOGICAL AND ENDOCRINOLOGICAL
Aseptic meningitis 5 10
Optic neuritis 2 4
ACTH deficiency 21 44
Other endocrin. manifestations 8 36





Gastrointestinal manifestation 13 50
Arthritis 7 30
Autoantibodies 12 40









Percentages are provided as fraction of affected patients relative to the number of patients
with information available.
the patient is infection free under continued Ig-substitution and
antibiotic prophylaxis. At age 16 hypopituitary central adrenal
insufficiency was diagnosed. Treatment was commenced with
replacement hydrocortisone.
Female P38 (Fam220) suffered from recurrent respiratory
infections during childhood, including pneumonia. Aged 31
years she was diagnosed with HBV-infection managed with
interferon-therapy for 4 years. At this time, CVID was also
diagnosed and immunoglobulin substitution was initiated. At 38
years, inhaled steroids were added to therapy due to intrinsic
bronchial asthma. During follow-up she was diagnosed with
psoriasis at age 42. She had several episodes of bronchitis, no
season predominant; pathogens were not found in sputum.
Bronchoscopy and BAL reported normal. She reported pinna,
nose pain and arthritic ribs pain. ANCA levels negative.
She developed saddle nose and tracheal stenosis and thus
polychondritis was diagnosed. The patient is now 56 years old,
alive, and suffering from mild depression, chronic liver damage
(liver steatosis) and polychondritis.
P41 (Fam246_01) was diagnosed with CVID at the age of
6 years with splenomegaly and autoimmune thrombocytopenia
with a minimum platelet count of 8,000/µl. Infectious symptoms
consisted at that time of a chronic obstructive bronchitis and
a chronic sinusitis, present since early childhood. Respiratory
work-up revealed bronchiectasis, obstructive ventilation disorder
and signs of interstitial lung disease. At the age of 5 years,
severe, aseptic meningitis developed. In addition, the patient
suffers from diarrhea of unknown etiology. Lymphadenopathy
prompted surgical resection and histological analysis showing
only very small germinal centers (Supplemental Figure S2).
Treatment was commenced with intravenous immunoglobulin
replacement and steroids and rituximab for the autoimmune
thrombocytopenia. Other family members refused genetic testing
or providing health status information for personal reasons.
P42 (Fam610_01) was diagnosed with CVID at the age
of 17 years and additional immune-mediated diseases, such
as autoimmune hepatitis and gluten-sensitive enteropathy.
Infectious symptoms included recurrent respiratory tract
infection, Pneumocystis jirovecii pneumonia, and diarrhea.
Dermatology revealed recurrent urticaria and pruritis and
eczematous lesions consistent with atopic dermatitis. As AP and
y-GT were elevated and ANA was positive, a liver biopsy was
performed consistent with autoimmune hepatitis. A duodenal
biopsy showed a mild ileitis with increased intraepithelial
lymphocytes in the terminal ileum and the right colon.
Treatment was initiated with intravenous immunoglobulins and
various immunosuppressive therapies including cyclosporine,
tacrolimus, mycophenolate, and prednisolone. This treatment
was stopped by the patient and later changed to intravenous
immunoglobulins which provoked allergic reactions. During
pregnancy at age 28 the clinical condition improved with
neither infection, nor urticaria or pruritis, and also improved GI
problems. A healthy baby girl was born with cesarean section due
to due to pre-eclampsia. At the age of 29 the patient presented
with fever and fatigue and was referred to a hematologist by
G.P because of abnormal CBC. She was diagnosed with AML
and died of severe aspergillus pneumonia after the first course
of chemotherapy.
Starting in infancy, this male P49 (Fam846_01) from Kosovo
suffered from recurrent respiratory tract infections including
pneumonia. In addition, he suffered from chronic sinusitis
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TABLE 5 | Immunological phenotype in patients with NFKB2 mutations.
Patient number 1 2 3 4 5 6 7 8 1011121314151617181920212223242526272829303133343841424344454647484950
Hypogammaglobulinemia
IgG ↓ nv ↓ ↓ ↓ ↓ ↓ nv ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓
IgM ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ nv ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓
IgA ↓ ↓ nv ↓ ↓ ↓ ↓ ↓ nv ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓
IgE ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓
Specific Antibody responses
Tetanus IgG nv nv ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ nv nv nvnvnvnv ↓ ↓ nvnv ↓
Diphtheria IgG nv ↓ ↓ ↓ ↓ ↓ ↓ nv nv ↓ ↓ ↓ ↓
Pneumococcal IgG ↓ ↓ nv ↓↓↓↓↓ nv nv nv ↓ nv nv nv
Hib IgG nvnv ↓↓↓ nv nvnv
T/B/NK cells
Lymphocytes ↓ nv ↓ ↑ ↑ ↑ nvnv ↑ ↑ ↑ ↑ nv ↑ ↑ nvnvnvnvnvnv ↑ ↑ ↓ ↑ nvnvnv ↑ nvnv nvnvnvnvnvnv ↑ nv
CD3+ cells ↓ nv ↓ ↑ ↑ ↑ ↓ ↑ ↑ ↑ ↑ ↑ nv ↑ ↑ nv ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↓ ↑ nv ↑ nvnv nv ↑ ↑ nvnv ↑ ↑ nv
CD3+CD4+ T cells ↓ nv ↓ nvnv ↓ ↓ ↑ nv ↑ ↑ ↑ ↑ ↑ ↑ ↑ nv ↑ ↑ ↑ nv ↑ ↑ ↑ ↓ ↑ nvnv ↓ nv ↑ nvnv ↓ nv ↑ ↑ nvnv ↑ ↑ nv
CD3+CD8+ T cells ↓ ↓ nv ↑ ↑ ↑ ↓ ↑ nvnvnvnv ↑ ↓ ↑ ↑ nvnvnv ↓ nvnv ↑ ↑ ↓ nvnvnvnvnv ↑ ↓ nv ↓ nv ↑ nvnvnv ↑ nv
CD19+ B cells ↓ nvnv ↓ ↓ ↓ ↑ nv ↓ nvnv ↓ ↑ ↓ ↑ ↓ ↓ ↓ nv ↓ ↓ ↓ ↓ nv ↑ ↓ nv ↓ ↓ ↓ nvnv ↓ ↓ ↓ nv ↓ ↓ ↓ ↓ nvnv
CD56+CD16+ NK cells ↓ ↓ ↓ ↓ ↓ ↓ ↑ ↓ ↓ nvnvnv ↑ nv ↑ nv nvnvnvnvnvnvnv ↑ ↓ nv nvnvnvnv ↓ ↑ nv ↓ nv ↑ nv
CD45RA+ of CD3+CD4+ ↓ nv nv ↓ ↓ ↑ ↑ ↑ nvnv ↑ ↑ nvnvnvnv ↑ nvnv ↑ nvnv nvnv
TCR repertoire vnvnvnvnvnvnvnvn ↓ ↓ nvnv nvnv
B cell subset
naive B cells* ↑ nv ↑ ↑ ↑ ↑ nv ↑ ↑ nvnv ↑ nv ↑ ↑ ↑ ↓ ↑ ↑ ↑ nvnv
switched memory** ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ nv
MZ/nonswitched mem*** ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↑ ↓ ↓ nvnv ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ nv nvnv
NK cells
NK cell cytotoxic activity nv ↓ nvnvnv nv ↓ nv nv
NK cell degranulation nv ↓ nvnvnv nv nv nv
T-Cell Proliferation
Mitogens (PHA, ConA, PWM) ↓ ↓ vnvnvnvnvnvnvnvnvn
Tetanus Antigen ↓ nv ↓ ↓ ↓ nvnv ↓↓
Candida Antigen ↓↓↓↓↓↓
PBMCs +Anti-CD3 Ab alone vnvn ↓ ↓ ↓ nvnv nv ↓
+Anti-CD3 Ab+Anti-CD28 Ab nv ↓ ↓ ↓ nv nv ↓
+Anti-CD3 Ab+IL-2 nv ↓↓↓↓
Other populations:
FoxP3+Tregs ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓
TfH cells ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓
Th17 ↓ ↓ ↓ nv ↓ nv
NKT cells ↓
MAIT ↓
Patient 1–7 carry proximal mutations, all other C-Terminal mutations. Black/arrow down, decreased; gray, no information provided; white nv, normal value; white/arrow up, increased;
MZ, marginal zone. *IgD+CD27− of CD19+, **IgD−CD27+, ***IgD+CD27+.
and chronic diarrhea since early childhood. At the age of 7
years, CVID, mild splenomegaly, and bilateral bronchiectasis
were diagnosed, and immunoglobulin substitution initiated.
The patient also suffered from recurrent herpes labialis and
zoster at dermatomes Th9/Th10 at the age of 4 and 9 years.
Blood analysis revealed a chronic CMV replication (4,000–10,000
copy numbers) without CMV-related organ complications.
GI work-up showed mild soor-esophagitis and epithelial
lymphocytic infiltrates in the GI-tract (Supplemental Figure S2).
At the age of 8 years, ACTH-deficiency was diagnosed
following a symptomatic hypoglycemia. Endocrinological work-
up revealed chronic prolactinemia and cranial MRI showed
no signs of hypophysitis microadenoma, or hypophysitis.
Pituitary autoantibodies were negative. The patient is now
12 years old, alive, and well under continued cortisone- and
immunoglobulin substitution.
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Patients With Proximal Truncating
Mutations and Expression of
p52-Like Proteins
P3 (Fam1506) is a male patient who presented in early
childhood with recurrent respiratory infections, otitis media,
chronic sinusitis and pneumonia. CVID was diagnosed at the
age of 7 years and immunoglobulin substitution was initiated.
He presented with vitiligo and eczema during the follow-
up. Chest CT showed bilateral bronchiectasis. He reported
worsening productive cough during the last 18 months.
Streptococcus pneumoniae was isolated from sputum. He has
chronic diarrhea and extensive small bowel nodular lymphoid
hyperplasia, but no evidence of malabsorption. He is alive, under
treatment with prophylactic antibiotics, inhaled therapy, and
immunoglobulin substitution.
P4 was born to non-consanguineous Indian parents without
significant family history and presented at 22 months of
age with high grade fever and cytopenias. He had no rash
or any apparent focus of infection. On clinical examination,
he had normal height and weight, had no dysmorphic
features. Besides massive hepatosplenomegaly he suffered from
multilineage cytopenias, hypofibrinogenemia, hyperferritinemia,
and histological evaluation of the bone marrow showed
hemophagocytosis. EBV viral capsid antibody was positive, but
there was no evidence of active EBV or CMV replication
assessed by PCR. Perforin stain, NK cell degranulation and T
cell cytotoxicity were normal excluding primary HLH. Due to
the fulfillment of >5/8 HLH criteria, he was treated according
to the HLH 2004 protocol, which was well-tolerated and showed
rapid response. After discontinuation of all treatments the patient
stayed well for now more than 2 years.
IMMUNOLOGICAL STUDIES
Decreased Lymphocyte Subpopulations in
Patients With NFKB2 Mutations
Besides standard immunological diagnostics some patients
underwent extensive immune-phenotyping. In P21 and P41
Th17 cells were found to be decreased as previously reported
in other patients (P13, P14). However, Th17 cells in P49 were
still within normal range (Table 5; Supplemental Table S1).
FoxP3+ T regulatory T cells (Treg) have previously been
described to be diminished (P12, P13, P14, P29, P30, P31) and
were also decreased in our patients P41 and P49 who could be
subjected to this assay. In line with previous reports, we observed
reduced frequencies of circulating T follicular helper (cTFH)
cells in CD4T cells in patients (P22-24, P41, and P49) with
C-terminal truncating NFKB2 mutations (Figures 2A,B).
However, when calculating the percentage of cTFH in memory
CD4T cells, P49 was in normal range, while the other four
patients were below the normal range (Figure 2B), indicating
that the reduction of circulating T follicular helper is not
exclusive, but also a consequence of the diminished memory
CD4T cell compartment in this case. P49 could also be further
assessed for NKT and CD161+Va7.2+CD8+MAIT cells, which
both were clearly decreased (Table 5; Supplemental Table S1).
Normal Natural Killer–Cell Cytotoxic
Activity in NFKB2-Mutated Patients
As one previous report indicated a defective natural killer–cell
cytotoxic activity in NFKB2-mutated CVID patients we tested
NK cell cytotoxicity as well as NK cell degranulation in P21, P41,
P49. P21 and P41 demonstrate a completely normal NK function,
but P49 showed normal NK degranulation and a mildly reduced
NK function when assessing the NK:T ratio, while the E:T ratio
was still normal (Figures 2C,D).
Normal Ability of T Cells to Proliferate in
NFKB2-Mutated Patients
Next, we addressed the question raised by previous reports
whether NF-κB2 haploinsufficiency could impair T cell
proliferation. However, T cells from all tested patients showed
a normal response toward mitogens, such as PHA and CD3
± CD28 stimulation as well despite different mutation classes
(P21, P38, P41, P49) (Figure 2E). However, we could confirm a
reduced proliferative response against candida antigen in P38.
In order to identify genotype-phenotype correlations and
common disease features we compared our findings to all 15
previous publications reporting NFKB2-mutated patients.
Clinical and Immunological Presentation in
NF-κB2 Haploinsufficiency
Previous to this publication (as of Sep 1st 2018), 35 cases of
NFKB2 mutations have been reported, summing up with our
novel 15 cases to a total of 32 families with 17 different mutations
(Table 1). 47/50 mutation carriers are alive, the deceased patients
died from a bleeding complication following abdominal surgery
at age 22, aspergillus pneumonia after chemotherapy necessary
due to AML at age 29 and complication of HSCT at the age
of 8 years. In addition, two further deceased relatives of other
patients (Brue et al.; Pt. C2, died at 9 years of age after BMT and
Maccari et al.; Pt. I.2 deceased 68 years of age after CMV-colitis)
are likely to have also been affected by mutations in NFKB2,
but formal genetic testing was not possible and thus these cases
have not been included in our cohort analysis (13, 20). All but
seven reported NFKB2-mutated patients carry mutations in the
C-terminal region, resulting in a non-processable p100 precursor
protein and thus functional p52 haploinsufficiency (Table 1). The
remaining reported four mutations cause proximal truncation
predicting bypassing of the precursor but expression of mutant
p52-like proteins (28).
The Clinical Phenotype in NF-κB2
Haploinsufficiency is Characterized by
Early-onset Antibody Deficiency, Clinical
Signs of T Cell Dysfunction, and
Autoimmunity Including Lymphocytic
Organ Infiltrations
PID was initially diagnosed in 46/50 of the affected individuals,
which were later shown to harbor mutations inNFKB2 (Figure 3;
Table 4). Two of the non-PID individuals are asymptomatic,
healthy NFKB2 mutation carriers (P7, P36), whereas one
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FIGURE 2 | Decreased T follicular helper (cTFH), but normal NK and T cell function in NFKB2-mutated patients. (A) Reduced frequency of circulating T follicular helper
cells (CXCR5posCD45RAneg) in CD4T cells of patients with NFKB2 mutation. FACS plots shows example staining of a healthy donor (HD) and P41. (B) Percentage
of CXCR5pos in CD45RA+ (left) and memory (CD45RAneg, right) CD4 T cells. (A,B) Dotted lines in graphs represent 95% percentile of 47 healthy donors. Values of
healthy donors are depicted as means ± SD. Statistical significance was assessed by Mann-Whitney test (**P < 0.01, ****P < 0.0001). (C) Normal NK and T cell
function. (C,D) PBMCs were stimulated either with medium alone or K562 cells for 2.5 h in presence of anti-CD107a-PE. Lytic exocytosis of NK cells (CD56+) are
measured by CD107a staining. (D) NK cytotoxicity was analyzed by standard 51Cr release assay. Target cell lysis by NK cells: PBMC were incubated with K562 target
cells in a standard 51Cr release assay. The percentage of NK cells among PBMC was measured by flow cytometry to determine the NK:target cell ratio. The gray
shaded area represents the range of normal values (5th−95th percentile). (E) T cell proliferation was measured by CFSE dilution after 1 week of stimulation with PHA
(1.25 ug/ml) or CD3 (100 ng/ml) with CD28 (200 ng/ml).
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FIGURE 3 | The clinical phenotype in NF-κB2 haploinsufficiency is characterized by early-onset antibody deficiency, clinical signs of T cell dysfunction, and
autoimmunity. (A) Fraction of affected patients relative to the whole cohort of patients of whom information was available with different clinical manifestations depicted
on the Y-axis. Manifestations below the solid line are relative to the 46 NFKB2-mutated patients with PID. (B) Absolute numbers of patients who are not affected by
different clinical manifestations are depicted on the left (open white bars), while the absolute number of reported patients affected are depicted to the right side (solid
gray bars).
individual suffers from isolated ACTH-deficiency only (P34), and
one suffers from rheumatoid arthritis manifesting at age 48 (P2).
Affected patients had a mean onset of symptoms of 5.9 years
(SD ± 8.7; median 4.0 range 0.1–48 years). 26/45 (57%) patients
with available information showed an onset of disease below the
age of 5 years. The most common presenting symptom were
respiratory infections (n= 30, 66%), followed by alopecia (n= 8,
18%). Other presenting symptoms were initial endocrinological
abnormalities without initial signs of PID (3), severe herpes
virus infection (2), and each one patient with meningococcal
meningitis, nephritis, arthritis, secondary HLH, panniculitis, or
autoimmune-hepatitis (Table 2).
In the PID group 33/46 (71%) patients were formally
diagnosed with CVID (mean age 10.5; SD ± 9.1; median 6.5)
and hypogammaglobinemia was noted in all the remaining
patients (Table 2).
The infection profile demonstrates upper respiratory
infections in 38/41 (93%) of the PID patients with available
clinical information. Lower respiratory infections were described
in 32/39 (82%) patients with bronchiectasis being reported in 13
of 23 (57%) cases with information available. Skin infections were
reported in 19/31 (61%) patients, most commonly due to herpes
species (13), but also bacterial causes (3), and severe molluscum
(2) (Figure 3; Tables 2, 4). Candida esophagitis was noted in
two patients, while four others suffered from susceptibility to
skin/nail infections due to candida. Opportunistic infections
included Pneumocystis jirovecii pneumonia in two patients,
mycobacterial disease in one and chronic CMV viremia or EBV
infections in three and two patients, respectively. Giardia was
noted in three patients and salmonella in one. Three patients
suffered from bacterial meningoencephalitis and other severe
bacterial infections, such as septic arthritis or septicemia, were
reported in three further patients. Further complications were
pericarditis, toxoplasmosis, recurrent conjunctivitis or chronic
hepatitis B each occurring in one patient each (Table 2).
ACTH-deficiency occurred in 21/48 (44%) mutation carriers
with a medium manifestation age of 8.2 years (SD ± 4.2, median
7.0, range 4–15 years). All but two patients suffered also of PID
preceding the occurrence of ATHC-deficiency (P32, P34). 8/22
(36%) of the patients showed other concomitant endocrinological
abnormalities, with five growth hormone deficiencies, four
hypothyroidism, and one child with prolactinaemia (Tables 3, 4).
Pituitary auto-antibodies were negative in all 6 patients that
have been subjected to this investigation. Cranial MRI showed
pituitary hypoplasia in three, but normal pituitary findings
in eight other affected patients. Interestingly, two unrelated
patients showed type 1 chiari malformation as an incidental
finding. Other neurological findings were single patient reports
of developmental delay, epilepsy, absence seizures, bell palsy
and depression. Interestingly, five patients were reported with
aseptic meningitis, two with optic neuritis, and one with
encephalitis (Table 3).
Concerning the autoimmunity in NF-κB2 haplodeficiency,
40 of 50 (80%) of patient were reported to suffer clinically
from some form of autoimmune manifestation. Alopecia was
present in 16/42 (38%) patients (12 alopecia totalis) with a mean
manifestation age of 4.4 years (SD ± 5.1; median 4.0, range
2–19 years). Trachyonychia was noted in 9/43 (21%) mutation
carriers (Figure 3; Table 3). The complete triad of trachyonychia,
ACTH-deficiency, and alopecia occurred in 7 patients, and
10 patients showed at least two manifestations simultaneously
(Table 3). Autoimmune cytopenias were reported in five patients,
gastrointestinal manifestations in 12, and 7 patients suffered of
arthritis. Interestingly, there was a surprisingly high number
of patients with some kind of lymphocytic organ infiltration
(15/29; 52%), mainly into the lung (5) and CNS (6). Other
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reported autoimmune manifestations were atopic eczema (3),
psoriasifrom dermatitis (2), vitiligo (2), nephritis (2), rosacea
(2), urticaria (2), as well as primary sclerosing cholangitis, lichen
planus pigmentosus, panniculitis, and one case of granulomatous
disease of the bone marrow. Autoantibodies, mainly TPO, have
been found in 12 of 25 investigated patients. Asthmawas reported
in 10 patients (Figure 3; Table 3).
Information on lymphoproliferation was scarcely available but
reported in 6/18 (33%) patients. Mild splenomegaly was the most
common manifestation, lymphadenopathy was rarely noted.
Lymph nodes were present in all of our patients; however, lymph
node architecture was disturbed showing very small germinal
centers in P41 (Supplemental Figure S2).
Four patients have developed a malignant disease: P5 suffered
from T-LGL leukemia and basal cell carcinoma at age 22; P11
from an EBV-negative non-Hodgkin lymphoma at age 23; and
P18 suffered from an urothelial carcinoma at age 37 and P41
suffered from AML at age 29 (Table 3).
Regarding treatment, 33/38 (84%) of PID patients
receive immunoglobulin substitution, at least three patients
received prophylactic antibiotics, and 13 patients required
immunosuppressive treatment because of autoimmune
manifestations (mainly steroids, but also 4× anti-CD20
and 1× cyclophosphamide as well as 1× MTX and
adalimumab) (Table 2).
Preserved T/NK Cell Numbers and
Function, But Disturbed B Cell
Differentiation, Hypogammaglobulinemia
and Decreased Lymphocyte
Subpopulations Are Consistent Features of
NF-κB2 Haploinsufficiency
Detailed immunological data was available from 43
patients (Table 5; Figure 4; Supplemental Table S1).
Hypogammaglobulinemia was consistently found in 34/36
(94%) patients for IgG, and 40/41 (98%) for IgM and IgA. No
patient had increased values of IgE. Specific response to antigens
were partially impaired with lack of titers against tetanus in 11/21
(52%), diphtheria 10/13 (77%), pneumococcus 8/15 (53%) and
HiB 3/8 (38%) of cases. Only 3/39 patients were lymphopenic,
while 22 had normal, and 14 had increased lymphocyte numbers.
T cell numbers were low in 4/37, normal in 10 and elevated in
23 patients. The elevated T cell numbers were largely due to
an expansion of CD4+ T cells (20/42). The fraction of naïve T
cells was decreased in 3/24 (13%) patients contrasting 7 (30%)
patients with increased percentages. TCR repertoire was normal
in 12/14 (86%) investigations (Table 5; Figure 4).
B cell numbers were reported to be decreased in 25/42 (60%)
reported cases. B cell differentiation proved to be impaired in
most investigated patients with an increase of naïve IgD+CD27−
of CD19+ B cells in 14/22 (63%), reduced marginal zone/non-
switched memory IgD+CD27+ cells in 19/25 (76%), as well as
reduced IgD−CD27+ switched memory B cells in 25/26 (96%)
(Table 5; Figure 4).
NK cell number was decreased in 11/37 (30%) patients. While
two reports suggested decreased NK degranulation in one and
slightly reduced NK cell cytotoxic activity in two patients (17,
18), another report of three other patients (carrying the same
mutation) proved normal NK cell cytotoxicity and degranulation
(25). In our hands, NK degranulation was normal in 3/3
further patients. Concerning NK-cytotoxicity, one patient with
a frameshift mutation (P49) showed near-normal values, while
two further patients (P21, P41) demonstrated fully functional
NK-cytotoxicity (Figure 2).
Concerning T cell function, reduced T cell proliferation
toward mitogens was reported in two patients, while 9 others had
normal proliferative activity. TCR stimulation by anti-CD3 alone
resulted in decreased proliferative response in 4/9 patients and
could not be rescued by addition of anti-CD28. While reduced
T cell proliferation against (antigen specific) TCR signaling was
found in 6/6 investigated patients against candida, 3/9 other
patients showed normal proliferative response toward tetanus
(Table 5; Figure 4).
In all 9 investigated patients Foxp3+ Treg cells were decreased.
as it was the case for all 14 patients investigated for T follicular
helper cells. Th17 cells were decreased in 4/6 of the patients
investigated. In addition, we tested a single patient for NKT and
CD161+Va7.2+CD8+ MAIT cells, which proved to be reduced
(Table 5; Figure 4).
DISCUSSION
Although both, canonical and non-canonical NF-κB signaling is
of central importance for various aspects of immunoregulation,
mutations in NFKB1 and NFKB2 have only very recently been
recognized as a molecular origin of the disease phenotype
in CVID. Here, we summarize the current knowledge of
the immunodeficiency phenotype associated with mutations
in NFKB2, in a cohort of 15 novel and 35 previously
described patients.
Clinical Presentation of Patients With
Damaging NFKB2 Mutations
Early-onset PID and a variable degree of autoimmunity became
evident in the vast majority of individuals with mutations
in NFKB2 (Tables 2–4; Figure 3). ACTH-deficiency occurred
in 44% of mutation carriers. In all but two patients this
manifestation was preceded by PID symptoms. Thus, occurrence
of immunodeficiency, mainly in terms of respiratory infections
typical for antibody deficiency, was the major presentation of
NFKB2-mutated patients before pituitary dysfunction became
apparent in the further course of disease (Table 2; Figure 3).
Besides immunodeficiency, autoimmunity in terms of alopecia
was the second most common initial disease manifestation.
Of note, nearly 60% of patients had an onset of disease
before the age of 5 years. Only two NFKB2 mutation carriers
were completely asymptomatic, one further patient suffered
from late-onset arthritis as the only manifestation (Table 2).
This illustrates that clinical expressivity and penetrance of
NFKB2 mutations resulting in DAVID-Syndrome, PID- or
isolated ACTH-deficiency are heterogenic and difficult to
predict based on the genetic alteration. However, the here
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FIGURE 4 | Preserved T/NK cell numbers and function, but disturbed B cell differentiation, hypogammaglobulinemia and decreased lymphocyte subpopulations are
consistent features of NF-κB2 haploinsufficiency. (A) Fraction of affected patients relative to the whole cohort of patients of whom information was available regarding
decreased values in the immunological phenotype depicted on the Y-axis. (B) Absolute numbers of patients with decreased values in different immunological assays
are depicted on the left (solid gray bars), while the absolute number of patients with either normal or increased values are depicted to the right side (open white bars).
described cohort underlies a high selection bias, as patients
were mainly recruited in immunology centers. Given the
heterozygous nature of NFKB2 related diseases and thus higher
probability of spontaneous occurrence, future studies focusing
on endocrinological cohorts are likely to identify further patients




From a clinical point of view, impaired B cell differentiation,
hypogammaglobulinemia, and subsequent susceptibility to
respiratory infections were present in most patients and thus
compatible with CVID (Figures 3, 4; Tables 2, 5). Interestingly,
the ability of mounting a specific antibody response was at least
partly preserved in more than 50% of the tested patients and
thus is in conflict to one ESID diagnostic criterion of CVID
(Figure 4; Table 5). However, marginal zone and switched
memory B cells were reduced in all PID patients, while total
B cell count was decreased in only about half of the affected
patients (Figure 4; Table 5). This suggests that B cell function
and differentiation, rather than their absolute number, play
essential roles in pathogenesis of immunodeficiency in patients
with NFKB2 mutations. The pivotal role of the B cell intrinsic
NF-κB2 pathway in humoral immune responses for B cell
survival and maturation has been demonstrated in humans
and murine models (29, 30). In addition, a cellular mechanism
for the observed phenotype is offered by the reduction of
cTFH-cells in p52 haploinsufficiency patients [Figures 2, 4;
Table 5 and Ref. (16)]. cTFH-cells are considered to be the
circulating counterparts of TFH in secondary lymphoid tissue
(31). TFH cells are specialized providers of T cell help to B
cells, and are essential for germinal center formation, affinity
maturation, and the development of high-affinity antibodies and
memory B cells (32). The non-canonical NF-κB pathway has
been shown to play an important role in TFH development by
regulating the expression of inducible T cell costimulator (ICOS)
ligand in B cells, and thus p52 haploinsufficiency is likely to
cause the disturbances of the humoral immune axis (32, 33). In
conclusion, a fully functional NF-κB2 pathway is required for
successful germinal center reactions by enabling survival and
maturation of B cells and generation of TFH cells and thus p52
haploinsufficiency results in the observed humoral phenotype.
More Than CVID: Immunodeficiency in
Patients With Damaging NFKB2 Mutations
Many patients affected by NFKB2 mutations demonstrated
a severe clinical course, which is not typical for isolated
antibody deficiency (Figure 3; Table 2). In addition, 13 patients
showed antibody deficiency before the fourth year of life which
also refutes the definition of CVID by the ESID diagnostic
criteria. A complicated disease course was associated with
clinical signs of T cell dysfunction, such as the susceptibility to
recurrent or severe herpes virus infections, candida infections,
and severe opportunistic infections, such as Pneumocystis
jivorecii pneumonia in two patients (Table 2). However, unlike
in combined immunodeficiency (CID), CD8+, CD4+, and
CD45RA+ naive T cell numbers were generally normal or
even increased (Figure 4; Table 5; Supplemental Table S1).
Functional testing showed normal T cell proliferation in our
hands, while previous reports produced conflicting results with
either impaired T cell proliferation (14, 15) or also normal
function (Figures 2, 4; Table 5) (20, 28). As the NF-κB2 pathway
is dispensable for the initial activation of T cells through TCR
signaling and rather important for regulating differentiation,
further studies in humans are needed to elucidate a possible
impairment of T cell function (34). Likewise, we could not
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confirm previous findings of impaired NK degranulation or
NK cell cytotoxic activity (17, 18), as both were normal or
merely marginally decreased in our cohort and one further study
(Figure 2) (25). Therefore, rather than severe impairment of
NK cell function or generally CID-like impaired T cell numbers
or function, we favor the hypothesis of a pathogen-specific
involvement of the NF-κB2 pathway being causative for the
observed clinical spectrum. For an instance, the marked and
hitherto underappreciated susceptibility toward herpes viruses
may be related to the crucial functions of CD27, CD40, and
LTβR, in the defense against herpes viruses, all of which signal
through p100/p52 (35, 36). On a cellular level, the observed
reduction of Th17 cells in the majority of investigated patients
may predispose to candida susceptibility (37). However, the
precise role of individual NF-κB subunits in the differentiation
of Th17 needs to be further studied, as the interplay between
NF-κB and RORγt in Th17 cells is not yet clear and two
patients demonstrated normal Th17 numbers. This finding is
in line with a mouse study, showing that the non-canonical
NF-κB pathway is dispensable for Th17 differentiation, but
essential for production of inflammatory cytokines by this
subpopulation (38). Correspondingly, studies in the cascade of
impaired non-canonical NF-κB-signaling and differentiation of
TFH, NKT, and MAIT cells will increase our understanding of
lymphocyte differentiation. An also noteworthy observation was
the development of HLH in infant P4. As NK-cell function was
assessed to be normal also in this patient, this further illustrates
our previous observation from 64 patients who developed
secondary HLH in the context of different PIDs including (S)CID
and lymphocyte activation defects (27, 39).
Autoimmunity in Patients With NFKB2
Mutations: Rather T Cell Mediated Than
Caused by Auto-Antibodies?
Our cohort analysis revealed that most NFKB2mutation carriers
suffered from variable and sometimes severe autoimmune
phenomena (Figure 3; Table 3). Besides ACTH-deficiency,
alopecia, various lymphocytic organ-infiltration, diarrhea, and
arthritis were common.
It is currently uncertain whether the ACTH-deficiency now
observed in 21/48 cases has an autoimmune origin. The initial
hypothesis of an involvement of NFKB2 mutations in pituitary
development, as indicated by hypoplasia in cMRI in the first
patient, cannot be supported anymore (11), as an increasing
number of affected patients had normal cMRI findings (Table 2).
Also, “Lym1”-mice carrying homozygous nonsense mutations
in Nfkb2, deleting the NIK-responsive phosphorylation domain
(Nfkb2Lym1/Lym1; c.2854A>T; p.Tyr868∗) show similar B cell
findings as patients with NFKB2 mutations but normal pituitary
anatomy (13). However, no autoantibodies against pituitary
proteins could be detected in all investigated patients. Likewise,
autoimmune-cytopenias, which usually account for 2/3 – 3/4
of all autoimmune manifestation in other CVID patients
(2), occurred only in 5/50 patients in the NFKB2 cohort.
Mechanistically, aberrantly activation of the NF-κB2 pathway
promotes prolonged B cell survival and renders self-reactive B
cells more resistant to negative selection, causing the generation
of autoantibodies in other systemic autoimmune diseases (40).
Altogether, this argues against a substantial production of
auto-antibodies in NF-κB2 haploinsufficient patients. Whether
the observed ACTH-deficiency is caused by T cell mediated
autoimmunity instead is currently unknown, but the frequent
presentation of lymphocytic organ infiltrations in half of the
reported cases, including infiltration of the CNS in six patients,
supports this hypothesis (Table 3).
Alopecia, predominately occurring early around the fifth year
of life, was a very common manifestation with 16/50 affected
patients and recognized as initial disease manifestation before
apparent signs of immunodeficiency in half of them. Alopecia is
understood to be a T cell dependent autoimmune disease (41).
Interestingly, NKT cells have recently been demonstrated to be
protective in alopecia. Thus, our single patient observation of
reduced NKT cells in addition to previous reports demonstrating
the importance of the NF-κB2 pathway for the development of
NKT cells (42), may offer an explanation for the high incidence
of alopecia in our cohort. Interestingly, trachyonychia, a distinct
form of nail dystrophy observed frequently in NFKB2-mutated
patients but also other diseases, is per se associated with alopecia
and mild to moderate lymphocytic infiltration (43). Therefore,
trachyonychia may facilitate another T cell mediated form of an
autoimmune manifestation in NFKB2-mutated patients.
An additional explanation for the distinct profile of
autoimmune manifestations observed in NFKB2-mutated
patients is likely to be caused by the disturbance of central
tolerance. NF-κB2 signaling is crucial for the development
of medullary thymic epithelial cells (mTEC), which mediate
immune tolerance by eliminating autoreactive T cells and
promote generation of Tregs cells (44). In addition, NF-κB2
signaling regulates the expression of autoimmune regulator
(AIRE). AIRE is a transcription factor in mTEC required for
expression of self-tissue antigens in the thymus, necessary
for the elimination of autoreactive T cells and induction
of central tolerance (44, 45). Mutations in AIRE results in
autoimmune-polyendocrinopathy-candidiasis-ectodermal
dystrophy (APECED) in which self-reactive T cells occur and
alopecia is a common feature in about 40% of cases (45). Further
support for the hypothesis of disturbed central tolerance due
to AIRE dysfunction in p52 haploinsufficiency is derived from
the murine Lym1 model, which also has reduced thymocyte
AIRE expression (46). In addition to the Addison-related
hyperpigmentation, the major skin manifestations of APECED
include chronic mucocutaneous candidiasis, nail dystrophy,
alopecia areata or totalis, and vitiligo (45), which collectively
closely resemble clinical aspects of p52 haploinsufficiency
(Table 3; Figure 3; Supplemental Figure S1). As a previously
underappreciated high number of NFKB2-mutated patients
further suffered from lymphocytic organ infiltrations, the
hypothesis of disturbed central tolerance due to NFKB2
mutations and primarily T cell mediated autoimmune processes
seems likely. Along this line of arguments (visceral) lymphocytic
infiltrations were also observed in Nfkb2Lym1/Lym1 mice (46).
A further explanation for the high incidence of autoimmunity
is offered by the reduced number of regulatory T cells in all
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patients investigated (Figure 4; Table 5). This finding may be
explained by the recent discovery of NF-κB activation being
critical for thymic Treg development aided bymTEC as discussed
above (44, 47).
Conclusion
We conclude that heterozygous damaging mutations in NFKB2
represent a distinct PID entity exceeding the usual clinical
spectrum of CVID. Impairment of the non-canonical NF-κB
pathway affects pivotal mechanisms of central tolerance as
well as function and differentiation of numerous lymphocyte-
subpopulations. Therefore, damaging NFKB2 mutations cause
a more severe form of PID with early-onset and a distinct,
multifaceted auto-immunity with primarily T cell mediated
autoimmune diseases, such as alopecia, lymphocytic organ
infiltration, and possibly ACTH-deficiency.
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